Hedeker Wealth LLC Has $681,000 Stock Holdings in AbbVie Inc. $ABBV

Hedeker Wealth LLC boosted its stake in shares of AbbVie Inc. (NYSE:ABBV) by 273.2% during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 3,669 shares of the company’s stock after buying an additional 2,686 shares during the period. Hedeker Wealth LLC’s holdings in AbbVie were worth $681,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Nuveen LLC acquired a new stake in AbbVie in the 1st quarter valued at about $1,819,154,000. Assenagon Asset Management S.A. raised its stake in AbbVie by 550.9% in the second quarter. Assenagon Asset Management S.A. now owns 4,332,054 shares of the company’s stock valued at $804,116,000 after buying an additional 3,666,521 shares during the period. Goldman Sachs Group Inc. lifted its position in shares of AbbVie by 31.6% in the first quarter. Goldman Sachs Group Inc. now owns 14,646,908 shares of the company’s stock valued at $3,068,820,000 after buying an additional 3,519,187 shares during the last quarter. Kingstone Capital Partners Texas LLC bought a new position in shares of AbbVie during the 2nd quarter worth approximately $581,817,000. Finally, Invesco Ltd. increased its holdings in shares of AbbVie by 17.5% during the 1st quarter. Invesco Ltd. now owns 8,367,049 shares of the company’s stock worth $1,753,064,000 after acquiring an additional 1,246,863 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Stock Up 0.1%

ABBV stock opened at $232.43 on Friday. The stock has a 50-day simple moving average of $224.89 and a two-hundred day simple moving average of $203.98. AbbVie Inc. has a twelve month low of $163.81 and a twelve month high of $244.81. The firm has a market capitalization of $410.79 billion, a PE ratio of 110.68, a PEG ratio of 1.42 and a beta of 0.50. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The company had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.58 billion. During the same period last year, the business earned $3.00 earnings per share. AbbVie’s revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, equities analysts predict that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be given a dividend of $1.73 per share. The ex-dividend date is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a yield of 3.0%. AbbVie’s dividend payout ratio (DPR) is 524.24%.

Wall Street Analyst Weigh In

ABBV has been the subject of a number of research analyst reports. BMO Capital Markets lifted their price objective on shares of AbbVie from $215.00 to $240.00 and gave the stock an “outperform” rating in a research report on Friday, September 12th. Cantor Fitzgerald set a $250.00 target price on shares of AbbVie and gave the stock an “overweight” rating in a report on Thursday, October 9th. UBS Group increased their price target on shares of AbbVie from $195.00 to $220.00 and gave the company a “neutral” rating in a report on Friday, November 7th. Daiwa America upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 7th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $289.00 target price (up previously from $284.00) on shares of AbbVie in a research report on Wednesday, November 5th. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $240.14.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.